• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Pregnancy and Postpartum Course
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Access Purchased Content
Home » Topics » General Psychiatry

General Psychiatry
General Psychiatry RSS Feed RSS

When First-Line Depression Treatments Don’t Cut It: Newer Antidepressants and Sometimes, Antipsychotics

July 1, 2017
Michael Gitlin, MD
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Michael Gitlin, MD Director of the Outpatient Mood Disorder Program at UCLA, as well as author of The Psychotherapist’s Guide to Psychopharmacology (Free Press) Dr. Gitlin has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
You’ve tried different SSRIs and then some, but your patient either can’t tolerate what you’ve prescribed or simply hasn’t experienced a lift in mood. Now what? Dr. Gitlin has some ideas.
Read More

When Depression Meds Fail, Transcranial Magnetic Stimulation Might Be Plan B

July 1, 2017
Jonathan E. Becker, DO
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Jonathan E. Becker, DO Assistant professor of clinical psychiatry and behavioral sciences at Vanderbilt University School of Medicine Dr. Becker has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Your patient has now failed four antidepressant medications, both alone and as cocktails. What else can you pull out of your bag of tricks? Dr. Becker suggests considering transcranial magnetic stimulation (TMS), which he maintains is underutilized. “Many of my colleagues right down the hall from me still don’t think of TMS for treatment or don’t know who to refer for it,” he says. “I think it should be more readily considered for a lot of patients out there.”

For a look at how TMS works, how effective it is, how it compares with electroconvulsive therapy (ECT), whether some brands of TMS machines are better than others, and what you have to do to make sure your patient’s health insurance plan picks up the tab, we spoke with Dr. Becker, who prescribes this treatment for some of his patients.
Read More

ConsumerLab.com: Guiding Patients Toward OTCs That Won’t Hurt Them

July 1, 2017
Richard Gardiner, MD
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Richard Gardiner, MD Psychiatrist in private practice in Potter Valley, CA Dr. Gardiner has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Dr. Gardiner recommends ConsumerLab.com to patients to “try to stop them from hurting themselves with mislabeled products or wasting their money” and to help determine whether a supplement might interfere with a medication he is prescribing.
Read More

NeuroStar’s Latest TMS System: 19 Minutes Is the New 40

July 1, 2017
Daniel Carlat, MD
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Daniel Carlat, MD Dr. Carlat has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
NeuroStar just announced that the FDA has cleared an updated version of its TMS system. Called the NeuroStar Advanced Therapy System, its primary claim to fame is that patients can receive a full TMS treatment in only 19 minutes, as opposed to the 40 minutes required with NeuroStar’s original system.
Read More

Learning Objectives, Antidepressants, TCPR, July/August 2017

July 1, 2017
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
After reading these articles, you should be able to…
Read More

CME Post-Test - Antidepressants, TCPR, July/August 2017

July 1, 2017
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
The post-test for this issue is available for one year after the publication date to subscribers only. By successfully completing the test you will be awarded a certificate for 2 CME credits.
Read More

Learning Objectives, Personality Disorders, TCPR, June 2017

June 1, 2017
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
After reading these articles, you should be able to…
Read More
CLINICAL Q&A

Diagnosing and Treating Borderline Personality Disorder

June 1, 2017
Joel Paris, MD and Daniel Carlat, MD
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Joel Paris, MD Professor, Department of Psychiatry, McGill University Dr. Paris has no relevant financial or other interests in any commercial companies pertaining to this educational activity. Daniel Carlat, MD Editor-in-chief, The Carlat Psychiatry Report Dr. Carlat has disclosed that they have no relevant financial or other interests in any commercial companies pertaining to this educational activity.
By and large, psychiatrists aren’t terribly comfortable when it comes to diagnosing and treating borderline personality disorder (BPD). Fortunately, diagnosing BPD is relatively easy and can often be done in 20–30 minutes. The key is to have a systematic approach, to ask high-yield questions, and to know how to efficiently follow up on responses.
Read More

Diagnosing and Treating Narcissism

June 1, 2017
Craig Malkin, PhD
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Craig Malkin, PhD Clinical psychologist. Lecturer, Harvard Medical School. Author of Rethinking Narcissism, published by HarperCollins Dr. Malkin has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Pathological narcissism is a desperate need to feel special—in fact, you can call it an addiction to feeling special. We tend to focus on one presentation, which is the loud, arrogant, conceited narcissist, but there are plenty of introverted narcissists (often called vulnerable or covert in the research), and these are the patients who often show up in our office. In this Expert Q&A Dr. Malkin shares his insight on helping narcissism patients.
Read More

FDA Approves First Drug to Treat Tardive Dyskinesia

June 1, 2017
Talia Puzantian
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Talia PuzantianTalia Puzantian Deputy editor, The Carlat Psychiatry Report Dr. Puzantian has disclosed that she has no relevant relationships or financial interests in any commercial company pertaining to this educational activity.
The U.S. Food and Drug Administration approved Ingrezza (valbenazine) for the treatment of tardive dyskinesia (TD), a disabling movement disorder that afflicts 10%–20% of people on chronic antipsychotic ­medication.
Read More
Previous 1 2 … 75 76 77 78 79 80 81 82 83 … 179 180 Next
Carlat Total Access Subscriptions: Get access to every article on the website.

Complete access to every article you search on the website.

Shop for Total Access
Free Psychiatry Updates
The latest unbiased psychiatric information sent to your inbox.
Specify Your Interests
Featured Book
  • MFB7e_Print_App_Access.png

    Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

    The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
    READ MORE
Featured Video
  • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
    General Psychiatry

    KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

    Read More
Featured Podcast
  • shutterstock_2637648401.jpg
    General Psychiatry

    Psychopharm Secrets: Coming Off Meds

    There’s a hidden placebo response to watch for when patients stop meds on their own.
    Listen now
Recommended
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report
  • The Carlat Psychotherapy Report

Contact

carlat@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.